###begin article-title 0
###xml 82 87 <span type="species:ncbi:9606">human</span>
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 487 492 <span type="species:ncbi:9606">human</span>
Endothelin (EDN) signalling plays a crucial role in cell differentiation, proliferation and migration processes. There is compelling evidence that altered EDN signalling is involved in carcinogenesis by modulating cell survival and promoting invasiveness. To date, most reports have focused on the oncogenic potential of EDN1 and EDN2, both of which are overexpressed in various tumour entities. Here, we aimed at a first comprehensive analysis on EDN3 expression and its implication in human breast cancer.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 425 430 425 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 716 723 <span type="species:ncbi:9606">patient</span>
###xml 744 751 <span type="species:ncbi:9606">patient</span>
EDN3 mRNA expression was assessed by Northern blotting in normal human tissues (n = 9) as well as in matched pairs of normal and tumourous tissues from breast specimens (n = 50). EDN3 mRNA expression in breast cancer was further validated by real-time polymerase chain reaction (PCR) (n = 77). A tissue microarray was used to study EDN3 protein expression in breast carcinoma (n = 150) and normal breast epithelium (n = 44). EDN3 promoter methylation was analysed by methylation-specific PCR in breast cell lines (n = 6) before and after demethylating treatment, normal breast tissues (n = 17) and primary breast carcinomas (n = 128). EDN3 expression and methylation data were statistically correlated with clinical patient characteristics and patient outcome.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 366 368 366 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 413 415 413 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 638 643 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 662 670 662 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 685 690 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 805 810 805 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 827 829 827 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 888 893 888 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 335 342 <span type="species:ncbi:9606">patient</span>
Loss of EDN3 mRNA expression in breast cancer, as initially detected by array-based expression profiling, could be confirmed by Northern blot analysis (> 2-fold loss in 96%) and real-time PCR (> 2-fold loss in 78%). Attenuated EDN3 expression in breast carcinoma was also evident at the protein level (45%) in association with adverse patient outcome in univariate (P = 0.022) and multivariate (hazard ratio 2.0; P = 0.025) analyses. Hypermethylation of the EDN3 promoter could be identified as the predominant mechanism leading to gene silencing. Reversion of the epigenetic lock by 5-aza-2'-deoxycytidine and trichostatin A resulted in EDN3 mRNA re-expression in vitro. Furthermore, EDN3 promoter hypermethylation was detected in 70% of primary breast carcinomas with significant association to loss of EDN3 mRNA expression (P = 0.005), whilst normal matched breast tissues revealed no EDN3 promoter methylation.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 291 296 <span type="species:ncbi:9606">human</span>
EDN3 is a frequent target of epigenetic inactivation in human breast cancer, potentially contributing to imbalanced EDN signalling commonly found in this disease. The clinical implication supports the view that EDN3, in contrast to EDN1 and EDN2, may act as natural tumour suppressor in the human mammary gland.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 680 681 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1044 1045 1044 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Endothelins (EDNs) are widely expressed cytokines in a variety of human tissues, including brain, skeletal muscle, pancreas, small intestine, testis and colon [1]. They constitute a family of small, vasoactive, 21-amino acid peptides referred to as EDN1, EDN2 and EDN3 [2]. EDNs are synthesised as large precursor proteins that are post-translationally cleaved to the biologically active 21-amino acid form [3]. They are involved in fundamental cellular networks like cell proliferation, migration and differentiation processes [4,5] by interacting with their corresponding cell surface-bound EDN-A (EDNRA) and EDN-B (EDNRB) receptors in an autocrine and also a paracrine manner [6-8]. A balanced regulation of this EDNRA/EDNRB interplay - also referred to as the endothelin axis (ET-axis)- is essential for, for example, homing processes to tissue destinations, where cells differentiate into numerous lineages such as the peripheral nervous system, structural and connective tissue components, cardiac cells or pigment-producing melanocytes [9].
###end p 11
###begin p 12
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 92 97 <span type="species:ncbi:9606">human</span>
There is now compelling evidence that imbalanced regulation of the ET-axis is implicated in human carcinogenesis, tumour progression and neo-angiogenesis [8,10-12]. During malignant cell transformation, the basic tissue architecture, which is maintained by basement membrane delineation, becomes disrupted [8]. This indicates the presence of crucial mediators that trigger the exchange of growth factors between the participating cells at the tumour invasion field. Essentially, such growth factor release is thought to enhance invasiveness, stimulate cell migration and promote neo-vascularisation [8]. Multiple signal transduction pathways are affected downstream from EDNRA/B. In the case of interaction of EDNs with EDNRA, a pertussis toxin-insensitive G protein becomes activated and promotes stimulation of phospholipase C, resulting in the transactivation of the mitogen-activated protein kinase pathway [13]. Second, EDN1 and EDN2 binding to EDNRA can activate p125 focal adhesion kinase and paxillin, both of which have been associated with increased tumour cell invasion. Moreover, EDNs are able to transduce the activation of anti-apoptotic signals through phosphatidylinositol-3-kinase and to stimulate neo-angiogenesis through vascular endothelial growth factor signalling [14]. These multiple ET-axis pathway implications may explain its various impairments of normal cellular integrity in case of an aberrant shift from balanced to imbalanced EDN signalling.
###end p 12
###begin p 13
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 320 325 <span type="species:ncbi:9606">human</span>
###xml 798 803 <span type="species:ncbi:9606">human</span>
Previously, EDN1 and EDN2 were found to be commonly overexpressed in a broad range of human tumour entities [8,11,12]. So far, most reports have focused on the role of EDN1 binding to EDNRA and its effects on tumour growth and neo-angiogenesis [8,11,13,15]. A role similar to that of EDN1 has been described for EDN2 in human breast cancer. Increased expression of EDN1 and EDN2, but not of EDN3, induced chemotaxis of breast cancer cells and increased tumour cell invasion through the basement membrane [4], although conflicting results have been reported by others [16]. In line with this, previous reports described a compensatory effect of EDN3 by negatively modulating the effects transduced by EDN1 [17] and demonstrated that downregulation of EDN3 is associated with upregulation of EDN1 in human tissues [18].
###end p 13
###begin p 14
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 125 130 <span type="species:ncbi:9606">human</span>
However, a comprehensive analysis of EDN3 expression in normal and cancerous breast tissues and its potential implication in human breast cancer has not been published so far. In our study, we investigated for the first time EDN3 mRNA and protein expression in a large number of primary breast tissues and breast cell lines. Furthermore, we identified the molecular mechanism by which EDN3 expression is deregulated in breast carcinomas.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 24 31 <span type="species:ncbi:9606">patient</span>
Cryo-conserved clinical patient material
###end title 16
###begin p 17
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1336 1337 1336 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 167 175 <span type="species:ncbi:9606">Patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 987 995 <span type="species:ncbi:9606">patients</span>
###xml 1176 1184 <span type="species:ncbi:9606">patients</span>
###xml 1273 1280 <span type="species:ncbi:9606">Patient</span>
Cryo-conserved clinical samples were obtained from breast cancer patients treated by primary surgery at the University Hospitals of Aachen, Dusseldorf and Regensburg. Patients receiving neo-adjuvant chemotherapy and patients with recurrent breast cancer were excluded. Resected tissue was snap-frozen in liquid nitrogen immediately after surgery. Only samples containing more than 70% of tumourous cells in haematoxylin/eosin-stained control sections were further processed (n = 128). For 17 samples, macroscopically normal breast tissues containing at least 30% of epithelial cells were available. In all cases, two board-certified pathologists agreed on the diagnosis of breast cancer. Tumour histology was determined according to the criteria of the World Health Organization (2003), whereas disease stage was assessed according to the UICC (Union Internationale contre le Cancer) [19]. Tumours were graded according to Bloom and Richardson, as modified by Elston and Ellis [20]. All patients gave informed consent for retention and analysis of their tissue for research purposes, and the institutional review boards of the participating centres approved the study. For 98 patients, follow-up data were available with a median time of 63 months (range 1 to 124 months). Patient characteristics of this cohort are summarised in Table 1.
###end p 17
###begin p 18
Clinicopathological parameters of cryo-conserved breast cancer specimens (n = 128)
###end p 18
###begin p 19
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 226 266 226 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNM Classification of Malignant Tumours </italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Due to rounding, percentages may not sum to 100. aOnly female patients with primary invasive breast cancer were included. bMedian 58 years, range 28 to 87 years. cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. NA, information not available.
###end p 19
###begin title 20
###xml 42 49 <span type="species:ncbi:9606">patient</span>
Formalin-fixed paraffin-embedded clinical patient material
###end title 20
###begin p 21
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 342 350 <span type="species:ncbi:9606">Patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 769 777 <span type="species:ncbi:9606">patients</span>
A tissue microarray (TMA) was created as described previously by Bubendorf and colleagues [21]. The formalin-fixed paraffin-embedded (FFPE) tissue sections were obtained from the archive of the Institute of Pathology, University of Regensburg, Germany. In all cases, two board-certified pathologists agreed on the diagnosis of breast cancer. Patients receiving neo-adjuvant chemotherapy and patients with recurrent breast cancer were excluded. All patients gave informed consent for retention and analysis of their tissues for research purposes, and the institutional review board of the participating centre approved the study. The TMA consisted of 150 primary tumours from malignant breast tissue and 44 normal breast specimens. Follow-up data were available for 146 patients with a median time of 77 months (range 1 to 148 months). Detailed tumour characteristics of this cohort are listed in Table 2.
###end p 21
###begin p 22
Clinicopathological parameters of formalin-fixed paraffin-embedded breast cancer specimens (n = 150)
###end p 22
###begin p 23
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 226 266 226 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNM Classification of Malignant Tumours </italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Due to rounding, percentages may not sum to 100. aOnly female patients with primary invasive breast cancer were included. bMedian 59 years, range 29 to 82 years. cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19]. dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. NA, information not available.
###end p 23
###begin title 24
Breast cell lines
###end title 24
###begin p 25
The non-cancerous breast cell lines MCF10A and MCF12A as well as the cancerous breast cell lines MCF7, SKBR3, MDA-MB231 and BT20 were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as recommended by the vendor.
###end p 25
###begin title 26
Northern blot expression analysis
###end title 26
###begin p 27
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 186 188 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 498 502 497 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3</italic>
###xml 679 681 678 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
Expression of EDN3 mRNA in various human tissues was tested using the commercial multiple-tissue Northern (MTN) blots I and II (Clontech, Heidelberg, Germany), containing 2 mug of poly A+ RNA per lane from 16 different human tissues (that is, blot I: heart, whole brain, placenta, lung, liver, skeletal muscle, kidney and pancreas; blot II: spleen, thymus, prostate, testis, ovary, small intestine, colon [no mucosa] and peripheral blood lymphocytes). Hybridisation was performed using 25 ng of an EDN3-specific 722-base pair (bp) polymerase chain reaction (PCR) product derived from (GenBank accession number ) (position: 968 to 1,707), which was verified by sequence analysis. 32P-labelling of the DNA probe was achieved using the Megaprime DNA Labeling System (Amersham Biosciences, now part of GE Healthcare, Little Chalfont, Buckinghamshire, UK), and hybridisation was performed in accordance with the recommendation the manufacturer. The cancer profiling array (CPA) I (Clontech) is a matched tumour/normal expression array consisting of cDNA synthesised from 50 breast carcinomas, 50 normal breast tissues and 3 breast cancer lymph node metastasis specimens. Hybridisation was performed in accordance with the recommendations the manufacturer as described above for the MTN blots. Hybridisation signals of both, MTN blots and the CPA, were evaluated by use of a STORM-860 phosphoimager (Molecular Dynamics, now part of GE Healthcare). Intensity ratios were calculated after normalising signals against the background.
###end p 27
###begin title 28
Nucleic acid extraction
###end title 28
###begin p 29
Frozen tissue samples and cell line pellets were dissolved in lysis buffer for subsequent DNA isolation using the QIAmp DNA Mini kit (Qiagen, Hilden, Germany) or for total RNA isolation by using TRIzol reagent (Invitrogen Corporation, Carlsbad, CA, USA) in accordance with the protocol supplied by the manufacturers.
###end p 29
###begin title 30
Reverse transcription of RNA
###end title 30
###begin p 31
###xml 174 177 173 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(6)</sub>
###xml 338 343 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 385 386 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 515 519 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
Of the extracted total RNA, 1 mug was reverse-transcribed using the Reverse Transcription System (Promega Corporation, Madison, WI, USA) by applying a mix of oligo-dT and pdN(6)-hexamer primers (1:2). The obtained cDNA was diluted (20 ng/muL) and test-amplified using intron-spanning primers for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). Primer sequences are provided in Table 3. PCRs were initiated as 'Hot Start' PCR at 95degreesC for 5 minutes and a hold at 80degreesC before the addition of 1 unit of GoTaq DNA polymerase (Promega Corporation). Cycle conditions were 95degreesC for 5 minutes, 35 cycles of 95degreesC for 1 minute, 60degreesC for 1 minute, 72degreesC for 1 minute and a final extension at 72degreesC for 10 minutes. PCR analyses were carried out in a PTC-200 cycler (Bio-Rad Laboratories, Inc., formerly MJ Research, Hercules, CA, USA). Amplificates were evaluated under ultraviolet light after 2% agarose gel electrophoresis containing ethidium bromide. Only samples yielding a specific 510-bp amplificate were further subjected to real-time PCR.
###end p 31
###begin p 32
Oligonucleotide primers used in this study
###end p 32
###begin p 33
EDN, endothelin; EDN3-M, endothelin-3 methylated; EDN3-U, endothelin-3 unmethylated; GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; TA, annealing temperature.
###end p 33
###begin title 34
Semi-quantitative real-time polymerase chain reaction
###end title 34
###begin p 35
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 271 272 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 295 297 295 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The Roche LightCycler system was used for semi-quantitative light cycler analysis in combination with the LightCycler DNA Master SYBR Green I Kit (Roche, Mannheim, Germany) as previously described [22]. Gene expression was quantified by the comparative cycle threshold (CT) method, normalising CT values to the housekeeping gene GAPDH and calculating relative expression values [23]. A commercially available normal breast cDNA pool (Clontech) was used as a breast reference standard. Primer sequences are listed in Table 3.
###end p 35
###begin title 36
Immunohistochemistry
###end title 36
###begin p 37
###xml 1012 1014 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 422 426 <span type="species:ncbi:9925">goat</span>
Paraffin sections of 2 mum were deparaffinised in xylene followed by rehydration in a decreasing ethanol series. Antigen retrieval was performed by pre-treatment in boiling citrate buffer (pH 6.0) in a microwave oven for 30 minutes (200 W). Immunohistochemistry (IHC) was performed using an NEXES Immuno Stainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) in accordance with the specifications of the manufacturer. A goat polyclonal EDN3-specific antibody (sc-21628; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used in a 1:150 dilution by using the ChemMate Envision Kit (DAKO, Hamburg, Germany). Counterstaining was performed by using Mayer's haematoxylin. The incubation with primary antibodies was omitted in negative controls. All analysed samples were stained without the knowledge of histopathological data. Cytoplasmic protein staining was semi-quantitatively scored by an experienced breast pathologist according to the well-established scoring system developed by Remmele and Stegner [24]. To verify staining specificity, the primary antibody was incubated with a 200 molar excess of blocking peptide (sc-21628 P; Santa Cruz Biotechnology, Inc.) for 2 hours prior to its application on test samples.
###end p 37
###begin title 38
CpG island prediction
###end title 38
###begin p 39
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1</italic>
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2 </italic>
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
EDN1, EDN2 and EDN3 genomic nucleotide sequences were taken from the Ensembl database and analysed for promoter CpG (cytosine-phosphate-guanine dinucleotide) islands in accordance with the method of Li and Dahiya [25]. A fragment of 2 kb in size, beginning 1 kb 5'-upstream from the annotated transcription start site (TSS) and ending 1 kb 3'-downstream, was analysed by applying the following criteria: island size of greater than 200 bp, guanine/cytosine content of greater than 60% and observed/expected CpG ratio of greater than 0.6.
###end p 39
###begin title 40
Bisulphite modification and methylation-specific polymerase chain reaction
###end title 40
###begin p 41
###xml 274 276 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 418 423 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 476 477 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 740 745 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
Of the genomic DNA, 1 mug was bisulphite-modified using the EZ DNA Methylation Kit (Zymo Research Corporation, Orange, CA, USA) and eluted in 20 muL of Tris buffer (10 mM). Methylation-specific PCR (MSP) was performed in accordance with the method of Herman and colleagues [26]. One microlitre of bisulphite-treated DNA was amplified using MSP primers that specifically recognise either the unmethylated or methylated EDN3 promoter sequence after bisulphite conversion (Table 3). To achieve high accuracy, each primer was designed to cover three CpG sites of template DNA. Commercially available universal poly-methylated DNA and unmethylated DNA (EpiTect Control DNA; Qiagen) were used as positive controls for methylated and unmethylated EDN3 sequences, respectively. MSP products were visualised under ultraviolet light after 3% low-range ultra agarose gel electrophoresis containing ethidium bromide (Bio-Rad Laboratories, Inc.). Promoter methylation status was interpreted in a binary qualitative fashion.
###end p 41
###begin title 42
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro demethylating treatment
###end title 42
###begin p 43
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
Cells were seeded at a density of 3 x 104 cells/cm2 in a six-well plate. The demethylation agent 5-aza-2'-deoxycytidine (DAC) (Sigma-Aldrich, Deisenheim, Germany) was added to a final concentration of 1 muM in fresh medium at days 1, 2 and 3 after seeding. Additionally, cells were exposed to 300 nM trichostatin A (TSA) (Sigma-Aldrich) on day 3 for 24 hours. Control cells without DAC/TSA were supplied with fresh medium on days 1, 2 and 3. DNA and RNA were extracted on day 4 as mentioned above.
###end p 43
###begin title 44
Statistical evaluations
###end title 44
###begin p 45
###xml 124 126 124 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 222 224 222 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 245 247 245 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 392 397 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1534 1536 1534 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
###xml 907 915 <span type="species:ncbi:9606">patients</span>
###xml 1076 1084 <span type="species:ncbi:9606">patients</span>
###xml 1261 1268 <span type="species:ncbi:9606">patient</span>
###xml 1364 1372 <span type="species:ncbi:9606">patients</span>
SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. All tests were performed two-tailed, and P values of below 0.05 were considered statistically significant. The non-parametric Mann-Whitney U test and the Student t test (paired and unpaired) were used to compare expression results between cancer tissues and normal tissues or between EDN3 mRNA expression and EDN3 methylation status. Contingency table analysis and Fisher exact tests were used to study the statistical association between clinicopathological factors and EDN3 protein expression or EDN3 promoter methylation status. Survival curves comparing patients with or without any of the factors were calculated using the Kaplan-Meier method, with significance evaluated by log-rank statistics. Breast cancer-specific survival (CSS) was measured from the day of surgery until tumour-related death and was censored for patients alive at last contact or in case of death unrelated to the tumour. Disease-free survival (DFS) was measured from surgery until disease relapse and censored for patients alive without evidence of relapse at the last follow-up. For EDN3 protein expression, a multivariate Cox proportional hazard model was employed to assess the relative risks on patient CSS and to test for independent prognostic relevance of clinical/investigational factors. Only patients for whom the status of all selected variables was known were included in the proportional hazard model (n = 121). The limit for reverse-selection procedures was P = 0.2. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions. For analyses, the following variables were categorised into binary values: small-sized (pT1) versus large-sized (pT2 to pT4), node-negative (pN0) versus node-positive (pN1 to pN3) and low-grade (G1 and G2) versus high-grade (G3) tumours.
###end p 45
###begin title 46
Results
###end title 46
###begin title 47
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 41 46 <span type="species:ncbi:9606">human</span>
EDN3 mRNA is differentially expressed in human breast cancer
###end title 47
###begin p 48
###xml 37 47 37 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 173 178 <span type="species:ncbi:9606">human</span>
###xml 471 476 <span type="species:ncbi:9606">human</span>
As previously reported, we performed in silico Northern blot analysis and RNA array-based expression profiling to identify novel candidate genes differentially expressed in human breast cancer [27,28]. In the latter approach, EDN3 was detected as one of the most frequently downregulated genes, showing substantial expression loss in 63% of breast carcinomas (data not shown). Therefore, we started a detailed analysis on EDN3 expression and its potential implication in human breast cancer.
###end p 48
###begin p 49
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3</italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 628 630 628 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 647 652 647 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b, c</xref>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 856 861 856 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 1058 1063 1058 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1154 1156 1154 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 1219 1224 1219 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1270 1272 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 1327 1332 1327 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 44 49 <span type="species:ncbi:9606">human</span>
An initial Northern blot analysis of normal human tissues demonstrates that EDN3 mRNA is abundantly expressed in a variety of non-malignant tissues, including pancreas, spleen, prostate, testis, small intestine and colon, with two major mRNA transcripts of 2.4 and 2.7 kb in size (Figure 1a). A breast cancer dot blot cDNA array was then hybridised with the same EDN3-specific probe. This showed a clear loss of EDN3 mRNA expression, as defined by a fold change (tumour versus normal) of greater than 2 (FC2), in 96% (48 of 50) of the analysed breast carcinoma samples and also in all three corresponding lymph node metastases (P < 0.001) (Figure 1b, c). To confirm this result, EDN3 mRNA expression was also assessed by real-time PCR in a set of 77 breast tumour tissues and 17 corresponding normal breast tissues. In breast carcinomas, downregulation of EDN3 expression by FC2 could be detected in 60 of 77 cases (78%; median: 21-fold) as compared with the normal breast reference standard (Figure 1d). This downregulation was still evident when comparing EDN3 expression among all tumour and normal breast tissues as illustrated by box plot analysis (P < 0.001) (Figure 1e) as well as when comparing fold changes of EDN3 expression among the 17 matched pairs (Figure 1f). In the latter analysis, 14 of 17 pairs (82%) showed EDN3 downregulation by FC2, with a median expression change of 13-fold.
###end p 49
###begin p 50
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 61 65 61 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3</italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 303 307 303 307 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 626 630 626 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 683 688 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 744 746 744 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 770 772 770 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 925 929 925 929 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 995 1000 995 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1138 1142 1138 1142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1196 1201 1196 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1263 1265 1263 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1287 1289 1287 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 1403 1407 1403 1407 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1423 1428 1423 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
Differential expression of EDN3 mRNA in human breast cancer. (a) A multiple tissue Northern blot hybridised with an EDN3-specific probe indicates ubiquitous expression of EDN3 mRNA in a variety of normal tissue types. In some tissues, both major EDN3 transcript variants are expressed (2.4 and 2.7 kb). (b) The same probe was hybridised to a breast cancer array containing cDNA pairs from 50 breast carcinoma tissues (T), 50 matched normal breast tissues (N) and 3 metastatic tissues. The outlined groups represent matched pairs, including the metastatic deposit, and consecutive numbers indicate specimen spots on the array. (c) Box plot demonstrating significant downregulation of EDN3 expression between normal and tumourous breast tissues (P < 0.001, Student paired t test; extreme value of specimen #29 omitted). Horizontal lines indicate group medians, and boxes indicate 25% to 75% quartiles, range, peak and minimum. (d) Real-time polymerase chain reaction analysis demonstrated loss of EDN3 expression in 78% of breast carcinomas by FC2 (fold change of greater than 2) (black bars) whilst 22% showed no deregulation (grey bars). (e) Box plot demonstrating the different distributions of EDN3 expression among normal breast tissues and breast carcinomas (P < 0.001, Mann-Whitney U test). Horizontal lines indicate group medians, and boxes indicate 25% to 75% quartiles, range, peak and minimum. (f) Fold changes of EDN3 expression in 17 matched pairs of normal breast and breast carcinoma samples revealed loss of expression in 13 cases (76%) and a median expression change of 13-fold. EDN3, endothelin-3.
###end p 50
###begin title 51
###xml 40 45 <span type="species:ncbi:9606">human</span>
Differential EDN3 protein expression in human breast cancer
###end title 51
###begin p 52
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 517 522 517 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a, b</xref>
###xml 973 978 971 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c, d</xref>
###xml 1038 1043 1036 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e, f</xref>
###xml 1421 1423 1417 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 1429 1431 1425 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1457 1459 1453 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 1465 1467 1461 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
To analyse whether loss of EDN3 expression in breast cancer is also evident on the protein level, we used a TMA comprising 150 invasive breast carcinomas and 44 normal breast tissue specimens. The specificity of the antibody applied was determined by the simultaneous use of blocking peptide against EDN3 in normal breast samples, which showed a clear decrease of overall EDN3 staining (Additional data file 1). EDN3 protein was clearly detectable in 75.0% (32 of 44) of normal breast tissue samples analysed (Figure 2a, b), as defined by an immunoreactivity score (IRS) of at least 8. The mean normal expression was determined to be IRS = 8.2 (+/- 3.8 standard deviations [SDs]). Expression was predominantly localised in luminal and basal epithelial cells of the normal breast and was weakly detectable in normal stromal compartments. In contrast, invasive breast carcinomas showed complete loss or reduced EDN3 expression (IRS < 8) in 45.3% (68 of 150) of cases (Figure 2c, d) and abundant EDN3 expression in 54.7% (82 of 159) (Figure 2e, f). Mean EDN3 expression in invasive breast carcinomas was determined to be IRS = 6.7 (+/- 4.0 SDs). EDN3 protein was rarely observed in tumour stroma (that is, was detectable only in those stromal cells adjacent to tumour cells with strong EDN3 expression). The difference of EDN3 expression between tumours and normal breast tissues was statistically significant (Mann-Whitney U test: P = 0.037; Student unpaired t test: P = 0.039).
###end p 52
###begin p 53
###xml 88 92 88 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 154 158 154 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 198 202 198 202 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 285 289 285 289 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 329 333 329 333 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 424 428 424 428 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 645 649 645 649 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 682 684 682 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 716 720 716 720 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(h) </bold>
###xml 40 45 <span type="species:ncbi:9606">human</span>
Differential EDN3 protein expression in human breast cancer and its clinical relevance. (a) Abundant EDN3 protein expression in normal breast epithelium. (b) Magnification of specimen shown in (a). (c) Representative invasive-ductal carcinoma showing moderate EDN3 protein expression. (d) Magnification of specimen shown in (c). (e) Representative invasive-ductal carcinoma with substantial loss of EDN3 protein expression. (f) Magnification of specimen shown in (e). Kaplan-Meier curves indicating that retaining high EDN3 protein expression (immunoreactivity score of at least 8) in the tumour is significantly associated with more favourable (g) breast cancer-specific survival (P = 0.022, log-rank test) but not (h) disease-free survival. Magnifications: x100 (a, c, e), x200 (b, d, f). EDN3, endothelin-3.
###end p 53
###begin title 54
###xml 51 58 <span type="species:ncbi:9606">patient</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
Loss of EDN3 expression is associated with adverse patient outcome in human breast cancer
###end title 54
###begin p 55
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 559 561 559 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2g</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2h</xref>
###xml 1024 1026 1024 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1042 1043 1042 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1205 1206 1205 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 1589 1591 1589 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 251 258 <span type="species:ncbi:9606">patient</span>
###xml 595 603 <span type="species:ncbi:9606">Patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
###xml 1186 1193 <span type="species:ncbi:9606">patient</span>
###xml 1209 1216 <span type="species:ncbi:9606">Patient</span>
###xml 1363 1370 <span type="species:ncbi:9606">patient</span>
To investigate a potential clinical relevance of EDN3 in breast cancer, we first analysed whether EDN3 protein expression is associated with clinicopathological parameters. In a bivariate analysis, differential EDN3 expression was not associated with patient age at diagnosis, tumour size, lymph node metastasis, histological grade, histological type, tumour focality or oestrogen or progesterone receptor status (Table 4). Interestingly, in a univariate survival analysis, we found a significant association between low EDN3 expression and unfavourable CSS (P = 0.022) (Figure 2g and Table 5). Patients with low EDN3 expression in the tumour had a mean CSS of 99 months (95% confidence interval [CI] 85 to 113 months) as compared with patients with tumours showing high EDN3 expression, which had a prolonged mean CSS of 116 months (95% CI 106 to 126 months). The visual impression of the Kaplan-Meier curves suggests also an association of EDN3 expression with DFS (Figure 2h), but this was statistically not significant (P = 0.167) (Table 5). Next, we performed a multivariate Cox regression analysis to test for independent significance of EDN3 expression as a prognostic factor in patient CSS (Table 6). Patient age at diagnosis, tumour size, lymph node metastasis, histological grade and EDN3 expression were included in the model. After reverse selection, patient age, lymph node status, grade and EDN3 expression remained significant in the Cox model, with low EDN3 expression displaying a twofold elevated risk of dying from breast cancer (hazard ratio 1.98, 95% CI 1.09 to 3.61; P = 0.025).
###end p 55
###begin p 56
Clinicopathological factors in relation to EDN3 protein expression
###end p 56
###begin p 57
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 169 209 169 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNM Classification of Malignant Tumours </italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3; IHC, immunohistochemistry.
###end p 57
###begin p 58
Clinicopathological factors in relation to disease-free and breast cancer-specific survival
###end p 58
###begin p 59
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 172 212 172 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNM Classification of Malignant Tumours </italic>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary invasive breast cancer were included. bLog-rank test. cSignificant data. dAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].eImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3; IHC, immunohistochemistry.
###end p 59
###begin p 60
Multivariate Cox regression analysis of clinicopathological factors potentially influencing breast cancer-specific survival, including EDN3 protein expression
###end p 60
###begin p 61
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
The variables were categorised according to Tables 4 and 5, except for age (continuous). aSignificant data. EDN3, endothelin-3.
###end p 61
###begin title 62
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
Loss of EDN3 mRNA expression in breast cancer cell lines
###end title 62
###begin p 63
###xml 6 7 6 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1</italic>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2 </italic>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 738 743 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2 </italic>
###xml 864 869 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1104 1109 1100 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 1152 1157 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
The NH2-terminal peptide structure of EDN3 differs considerably in essential amino acids between residues 2 and residues 4 to 7 from those of EDN1 and EDN2 (Figure 3a). This region bulges out of the basic EDN structure and has been reported to represent a major domain for binding specificity to EDN receptors and thus is critical in EDN signalling activity [29]. Because we found that EDN3 expression is frequently lost in breast cancer tissues, we next compared EDN1, EDN2 and EDN3 mRNA expression in breast cell lines in parallel. EDN1 was much more strongly expressed in all cancerous cell lines (MCF7, SKBR3, MDA-MB231 and BT20) than in non-cancerous MCF12A cells (Figure 3b), showing a mean upregulation of 13.9-fold (+/- 7.8 SDs). EDN2 was more strongly expressed in SKBR3 cells but less expressed in MCF7, MDA-MB231 and BT20 as compared with MCF12A cells. EDN3 expression, however, was clearly downregulated in all cancerous cell lines as compared with non-cancerous cells, revealing a mean expression of 0.008 (+/- 0.009 SDs) of that found in MCF12A cells (set to 1). Therefore, upregulation of EDN1 appears to coincide with downregulation of EDN3 in breast cancer cell lines.
###end p 63
###begin p 64
###xml 64 68 64 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 401 403 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 445 446 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 704 706 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 817 821 813 817 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 867 872 863 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 888 893 884 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 897 902 893 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2 </italic>
###xml 920 925 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 1008 1013 1004 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 122 127 <span type="species:ncbi:9606">human</span>
Endothelin (EDN) mRNA expression analysis in breast cell lines. (a) Alignment of the primary amino acid (aa) structure of human EDN1, EDN2 and EDN3 after post-translational cleavage to the biologically active 21-aa form [4]. The secondary structure consists of single alpha-helices containing two disulphide bonds that hold them in a conical spiral shape, joining cysteins at positions 1-15 and 3-11 [53]. EDN3 structure differs mainly in the NH2-terminal region from the structure of EDN1 and EDN2. This region forms a bulge out of the basic EDN structure and has been reported to represent a major domain for binding specificity to EDN receptors and thus is critical in endothelin signalling activity [29]. Numbers indicate consecutive aa residues, and aa residues are indicated in universal single-letter aa code. (b) Real-time polymerase chain reaction comparing EDN3 expression with EDN1 and EDN2 expression. While EDN1 is overexpressed in cancerous breast cell lines (MCF7, SKBR3, MDA-MB231 and BT20), EDN3 expression is abrogated in the same malignant cells as compared with MCF12A cells (set to 1 in each diagram).
###end p 64
###begin title 65
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
Methylation of the EDN3 promoter in breast cancer cell lines
###end title 65
###begin p 66
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2 </italic>
###xml 498 503 498 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 825 830 825 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 876 881 876 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 942 947 942 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 1074 1076 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4e</xref>
###xml 1227 1232 1227 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1290 1295 1290 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1341 1346 1341 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1421 1426 1421 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1490 1499 1490 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1537 1542 1537 1542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1684 1689 1684 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1752 1754 1752 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4e</xref>
###xml 1818 1823 1818 1823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1847 1849 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4f</xref>
###xml 1945 1950 1945 1950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 2045 2050 2045 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 2115 2120 2115 2120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 601 606 <span type="species:ncbi:9606">human</span>
###xml 971 976 <span type="species:ncbi:9606">human</span>
Since promoter hypermethylation is responsible for transcriptional silencing of important tumour suppressor genes in various human cancer types [30], we searched all three EDN genes for the presence of CpG islands in their promoter region. A region of high CpG density in the EDN3 nucleotide sequence was identified as a CpG island (Figure 4a), whereas the CpG density in EDN1 and EDN2 is lower and does not define a CpG island under the selected criteria. To analyse the methylation status of the EDN3 CpG promoter (Figure 4b), we performed MSP with DNA after bisulphite treatment from non-malignant human tissues and three non-malignant and four malignant breast cell lines. The utilised MSP primers were tested on a dilution series of poly-methylated DNA, which revealed a sensitivity of 0.01 (1%) in detecting methylated EDN3 DNA molecules in a background of unmethylated EDN3 DNA molecules (Figure 4c). We observed no methylation of the EDN3 promoter in HMEC cells, human placental tissue, peripheral blood lymphocytes (Figure 4c) or non-malignant MCF10A cells (Figure 4e). A weak methylation signal was detected in non-malignant MCF12A cells. Of the malignant breast cell lines, MDA-MB231 and MCF7 harboured a methylated EDN3 promoter. In BT20 cells, both unmethylated and methylated EDN3 promoter sequences could be detected, whereas EDN3 was unmethylated in SKBR3 cells. Next, we analysed the association between EDN3 expression and promoter methylation in six breast cell lines by in vitro demethylating their DNA and assessing EDN3 mRNA expression after the treatment. A clear conversion of methylation could be observed in cell lines that were originally methylated in the EDN3 promoter region (that is, in MDA-MB231 and MCF7 cells) (Figure 4e), resulting in 47-fold and 28-fold increases, respectively, in EDN3 mRNA expression (Figure 4f). In BT20 cells, however, the demethylating effect was weaker and led to a 3-fold induction of EDN3 transcription. In weakly methylated MCF12A cells, the conversion of methylated alleles induced EDN3 expression by 5-fold, whereas no substantially altered change of EDN3 expression could be detected in unmethylated MCF10A (1.6-fold) or SKBR3 (1.0-fold) cells.
###end p 66
###begin p 67
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 57 61 57 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1</italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2 </italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 397 401 397 401 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 656 660 656 660 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 681 690 681 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 881 885 881 885 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 889 894 889 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 954 958 954 958 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 958 963 958 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1155 1160 1155 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 1462 1466 1462 1466 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1466 1471 1466 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 2019 2024 <span type="species:ncbi:9606">human</span>
EDN3 promoter methylation analysis in breast cell lines. (a) Prediction of CpG islands in EDN family genes. A 2-kb genomic nucleotide sequence of EDN1, EDN2 and EDN3 was analysed with MethPrimer software [25]. A region of particularly high CpG density (red vertical bars) in the EDN3 nucleotide sequence proximal to the transcription start site (TSS) was identified as a CpG island (blue shaded). (b) Schematic representation of the EDN3 gene fragment that has been analysed for methylation. Arrows indicate hybridisation sites of methylation-specific polymerase chain reaction (MSP) primers, +1 indicates TSS, and vertical bars depict CpG dicnucleotides. (c) A dilution series of in vitro poly-methylated DNA with unmethylated DNA demonstrates the sensitivity of the applied MSP primers, which detect at least 1% of methylated DNA (M) in a background of unmethylated DNA in MSPs. (d) The EDN3 promoter is unmethylated in HMEC and non-malignant tissues. (e) EDN3 methylation analysis in breast cancer cell lines before (-) and after (+) treatment with demethylating (DAC) and histone reacetylating (TSA) drugs. In cell lines originally showing methylated EDN3 promoter alleles (MCF12A, MDA-MB231, MCF7 and BT20), a conversion of methylation was achieved as indicated by a gain of signal strength for non-methylation (U) and loss of signal strength for methylation (M), whereas in originally unmethylated cells (MCF10A and SKBR3), the treatment showed no effect. (f) EDN3 mRNA expression analysis as determined by real-time polymerase chain reaction before (-) and after (+) the demethylating treatment illustrates strong re-expression in those cell lines that were substantially demethylated (MCF7: 28-fold; MDA-MB231: 47-fold) as compared with cell lines showing weaker demethylation (BT20: 3-fold; MCF12A: 5-fold) or unmethylated cells (MCF10A: 1.6-fold; SKBR3: 1.0-fold). bp, base pairs; CpG, cytosine-phosphate-guanine dinucleotide; DAC, 5-aza-2'-deoxycytidine; EDN, endothelin; GC, guanine-cytosine content; HMEC, human mammary epithelial cells; PBL, peripheral blood lymphocyte; Plac, placental tissue; TSA, trichostatin A.
###end p 67
###begin title 68
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
Frequent EDN3 promoter methylation in primary breast carcinomas
###end title 68
###begin p 69
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 668 674 <span type="species:ncbi:8164">Suzuki</span>
Next, we analysed EDN3 promoter methylation in primary breast cancer as well. In total, 89 of 128 breast carcinoma samples (69.5%) showed EDN3 promoter methylation (for example, #5 in Figure 5a). The remaining breast carcinoma samples (39 of 128; 30.5%) were not affected by this epigenetic modification (for example, #13 in Figure 5b). None of the 17 normal breast tissues exhibited EDN3 promoter methylation. Cancerous tissues yielded a PCR product with primers specific for the unmethylated EDN3 promoter sequence in all cases, due to non-malignant contaminants (stromal cells and endothelial cells) present in the bulk tumour tissue, as has also been described by Suzuki and colleagues [31].
###end p 69
###begin p 70
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 52 56 52 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 344 353 344 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 383 387 383 387 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 580 585 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3</italic>
###xml 680 684 680 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3</italic>
###xml 707 709 707 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 731 733 731 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
EDN3 promoter methylation in primary breast cancer. (a) Methylation-specific polymerase chain reaction (MSP) was performed on bisulphite-treated DNA from breast carcinomas (T) and matching normal breast tissue (N). Representative MSP results from eight patients are shown. MSP controls were commercially available poly-unmethylated (poly-U) or in vitro poly-methylated (poly-M) DNA. (b) Box plot demonstrating the significant association between EDN3 promoter methylation and EDN3 mRNA expression in these tissues. For 71 samples, EDN3 expression has been assessed in parallel to EDN3 promoter methylation. EDN3-methylated tumours show significant downregulation as compared with EDN3-unmethylated tumours (P = 0.005, Mann-Whitney U test). Horizontal lines indicate group medians, and boxes indicate 25% to 75% quartiles, range, peak and minimum. EDN3, endothelin-3; M, methylated; U, unmethylated.
###end p 70
###begin p 71
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 484 489 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 608 610 608 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 632 634 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
We next aimed to analyse whether EDN3 promoter methylation was associated with EDN3 mRNA expression in these tissues. For 71 breast cancer specimens, both EDN3 methylation and EDN3 mRNA expression have been investigated in parallel. Figure 5b shows the distribution of EDN3 mRNA expression among these two groups. While carcinoma samples with unmethylated EDN3 promoter exhibited similar EDN3 mRNA expression as compared with normal breast tissues (Figure 1e), breast carcinomas with EDN3 methylation exhibited a significant downregulation of EDN3 mRNA expression as compared with EDN3 unmethylated samples (P = 0.005, Mann-Whitney U test).
###end p 71
###begin p 72
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T7">7</xref>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 542 544 542 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 575 577 575 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 261 268 <span type="species:ncbi:9606">patient</span>
###xml 529 536 <span type="species:ncbi:9606">patient</span>
###xml 562 569 <span type="species:ncbi:9606">patient</span>
Finally, we asked whether EDN3 promoter methylation may be of clinical relevance in human breast cancer, as we have previously found for EDN3 protein expression. In a univariate analysis, the EDN3 methylation status in breast carcinomas was not associated with patient age at diagnosis, tumour size, lymph node metastasis, histological grade, histological type or oestrogen or progesterone receptor positivity (Table 7). In contrast to EDN3 protein expression, EDN3 promoter methylation was significantly associated neither with patient CSS (P = 0.703) nor with patient DFS (P = 0.632) (data not shown).
###end p 72
###begin p 73
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
Clinicopathological parameters in relation to EDN3 promoter methylation
###end p 73
###begin p 74
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 169 209 169 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNM Classification of Malignant Tumours </italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19]. dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3.
###end p 74
###begin title 75
Discussion
###end title 75
###begin p 76
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 379 384 <span type="species:ncbi:9606">human</span>
###xml 689 694 <span type="species:ncbi:9606">human</span>
The involvement of EDNs in tumourigenesis has been described in several reports [4,10,15]. In contrast to the potentially oncogenic role of EDN1 and EDN2, there is still little knowledge about the role of EDN3 in cancer initiation or progression. A recent study demonstrated abundant expression of EDN1 and EDN2 but complete absence of EDN3 expression in a representative set of human breast cancer cell lines [12]. Because we have previously found that EDN3 mRNA expression is downregulated in primary breast carcinomas as compared with normal breast tissues [27,28], we aimed in this report to provide the first comprehensive analysis of EDN3 expression and its potential implication in human breast cancer.
###end p 76
###begin p 77
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1376 1377 1376 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1378 1380 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1646 1647 1646 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1710 1712 1710 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1732 1734 1732 1734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1770 1772 1770 1772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 2312 2313 2312 2313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 2314 2316 2314 2316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 628 633 <span type="species:ncbi:9606">human</span>
###xml 2170 2177 <span type="species:ncbi:9606">patient</span>
###xml 2529 2534 <span type="species:ncbi:9606">human</span>
Initially, we screened various non-malignant epithelial tissues for EDN3 mRNA expression and also analysed its expression using a breast cancer cDNA dot blot array. Besides abundant expression in several human tissues, EDN3 was strongly expressed in normal breast samples, providing evidence for a functional role in epithelial tissues such as the mammary gland. In contrast, most matched breast carcinomas showed diminished EDN3 mRNA expression both on the cDNA dot blot array and by real-time PCR analysis. This finding supports the current evidence that EDN3 may exert a functional role divergent to that of EDN1/EDN2 in the human mammary gland [18]. A further TMA analysis revealed that EDN3 protein is abundantly expressed in normal breast whereas its expression is reduced in a large fraction of breast carcinomas. Frequency differences may arise due to the use of different techniques (real-time PCR versus IHC) on separate tumour cohorts (fresh frozen versus FFPE) and accomplishing different scoring systems. Loss of EDN3 protein expression was not associated with relevant clinicopathological factors. For instance, it occurred with almost equal frequency among all tumour sizes (pT1 to pT4), suggesting that it may be an early event in the development of infiltrating breast carcinoma. Since EDN3 is thought to counterbalance the effects mediated by EDN1 and EDN2 [4,18], we propose that loss of EDN3 expression could actively enhance overexpression of the ET-axis. Recently, upregulation of ET-axis members was found to be associated with higher histological grade, lymph node metastasis and lymphovascular invasion in breast cancer [5] and also with advanced tumour progression in ovarian cancer [32], prostate cancer [33], Ewing sarcoma and neuroblastoma [11]. A systematic expression analysis on larger breast carcinoma cohorts and metastatic deposits is now required, including all three EDNs and EDNRA/EDNRB. This will unravel in detail the inter-relationship between EDN3 expression loss and upregulation of EDN1/2 and EDNRA/B as well as its association with breast tumour progression. In our study, loss of EDN3 expression was associated with adverse patient outcome. So far, overexpressions of EDN1 and EDNRA were already reported as being associated with impaired survival in breast cancer [5,34]. Our findings support the view that an imbalanced ET-axis is of pivotal relevance in breast cancer biology and that EDN3, unlike other members of the ET-axis, may represent a novel tumour suppressor gene in the human mammary gland.
###end p 77
###begin p 78
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN1 </italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN2</italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 363 368 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 575 580 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1183 1189 1183 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDNRB </italic>
###xml 1364 1366 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1476 1482 1476 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDNRB </italic>
###xml 1672 1673 1672 1673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1969 1971 1969 1971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 731 738 <span type="species:ncbi:9606">patient</span>
Addressing the molecular cause by which EDN3 expression becomes abrogated, we found that the EDN3 gene promoter, unlike EDN1 and EDN2, contains a CpG island as a potential substrate to aberrant hypermethylation and consequently gene inactivation. Indeed, we detected EDN3 promoter methylation in cancerous breast cell lines in functional association with loss of EDN3 mRNA expression. Moreover, a hypermethylated EDN3 promoter was also detected in 70% of breast carcinoma specimens in significant association with loss of EDN3 expression. We therefore conclude that aberrant EDN3 methylation is a tumour-specific event and the predominant mechanism leading to EDN3 expression loss in breast cancer. However, it remains elusive why patient survival was not associated with EDN3 methylation as it was with loss of EDN3 protein expression. In fact, only very few studies detected such outcome association on both molecular levels (for example, for SFRP1 [22,35] or ITIH5 [36]), probably due to considerable sensitivity differences of the available detection techniques as well as further genetic or epigenetic alterations contributing to the loss of a gene's expression. Interestingly, EDNRB was previously described to be methylated in numerous tumour entities, such as lung, colon, prostate, bladder, kidney, liver, oesophageal, nasopharyngeal cancer and leukemia [37-45], but to the authors' knowledge, never in gynaecological tumours. So far, there has been no evidence that EDNRB becomes methylated in breast carcinomas since a previous study demonstrated strong EDNRB expression in all invasive ductal carcinoma samples and in all analysed cancerous breast cell lines [4]. Notably, an ET-axis expression pattern similar to that of breast cancer was recently found in cervical cancer; that is, upregulation of EDN1, EDN2, EDNRA and EDNRB expression was accompanied by downregulation of EDN3 expression in cancerous cervix as compared with normal cervical epithelium [46]. This suggests that a decrease of EDN3 expression accompanied by an increase of EDNRB expression may be a particular feature of gynaecological tumour entities.
###end p 78
###begin p 79
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 815 816 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 944 949 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
Since the ET-axis represents crucial decisive elements for the direction of tumour growth, invasion and neo-angiogenesis, it provides a promising intervention point for molecular targeted therapies. EDNR antagonists have been proven as potent and specific ET-axis inhibitors that block cellular pathways implicated in tumour growth. The drug bosentan, which targets both EDNRA and EDNRB, inhibits tumour growth, vascularisation and bone metastasis in breast cancer [47]. Atrasenatan, targeting EDNRA, is capable of inhibiting proliferation and cancer growth-promoting processes [48,49]. In addition, blockers of EDNRA resensitised cancer cells to paclitaxel-induced apoptosis, as observed in ovarian, prostatic, cervical and nasopharyngeal cancer cell lines [49-51] as well as in primary ovarian and breast cancer [5,52]. Our study adds a novel aspect to therapeutically targeting the ET-axis in breast cancer. Since the epigenetic lock of the EDN3 gene is potentially reversible by DNA methyltransferase (DNMT) or histone acetyltransferase (HDAC) inhibitors or both, these drug classes may provide a future option in a combined treatment consisting of a decrease in EDN1/2 signalling by blocking EDNRs together with the reactivation of EDN3 expression by DNMT and HDAC inhibitors. Apparently, molecular rebalancing of the ET-axis in cancerous cells may be most efficiently achieved by targeting all deregulated axis molecules.
###end p 79
###begin title 80
Conclusions
###end title 80
###begin p 81
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EDN3 </italic>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 246 251 <span type="species:ncbi:9606">human</span>
###xml 664 669 <span type="species:ncbi:9606">human</span>
In summary, our study contributes to the understanding of deregulated EDN signalling commonly observed in human tumours. EDN3 expression, in contrast to abundant EDN1 and EDN2 expression, becomes frequently inactivated by promoter methylation in human breast cancer, potentially causing aberrant activation of the ET-axis, which in turn may promote this disease. We therefore conclude that EDN3 may be an interesting future target for an epigenetic therapy. Forced EDN3 re-expression by DNA demethylation agents in conjunction with inhibitors of EDNRs may rebalance ET-axis-mediated cellular signalling to a more normal status, thus having a therapeutic impact in human breast cancer.
###end p 81
###begin title 82
Abbreviations
###end title 82
###begin p 83
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
bp: base pair(s); CI: confidence interval; CPA: cancer profiling array; CpG: cytosine-phosphate-guanine dinucleotide; CSS: breast cancer-specific survival; CT: cycle threshold; DAC: 5-aza-2'-deoxycytidine; DFS: disease-free survival; DNMT: DNA methyltransferase; EDN: endothelin; EDNR: endothelin receptor; ET-axis: endothelin axis; FC2: fold change of greater than 2; FFPE: formalin-fixed paraffin-embedded; GAPDH: glyceraldehyde-3-phosphate-dehydrogenase; HDAC: histone acetyltransferase; IHC: immunohistochemistry; IRS: immunoreactivity score; MSP: methylation-specific polymerase chain reaction; MTN: multiple-tissue Northern (blot); PCR: polymerase chain reaction; SD: standard deviation; TMA: tissue microarray; TSA: trichostatin A.
###end p 83
###begin title 84
Competing interests
###end title 84
###begin p 85
The authors declare that they have no competing interests.
###end p 85
###begin title 86
Authors' contributions
###end title 86
###begin p 87
FW participated in the conception and design of the study and carried out the gene expression analyses, immunohistochemical studies and methylation experiments. JV performed statistical evaluations, participated in data interpretation and wrote the manuscript. OG provided expertise in DNA methylation analysis and critically revised the manuscript. AH provided clinical samples and clinicopathological data, performed data interpretation and critically revised the manuscript. ME participated in data interpretation and critically revised the manuscript. RK participated in the design and coordination of the study and critically revised the manuscript. ED planned and coordinated the study and critically revised the manuscript. All authors read and approved the final manuscript.
###end p 87
###begin title 88
Supplementary Material
###end title 88
###begin title 89
Additional data file 1
###end title 89
###begin p 90
A PDF file that demonstrates the specificity of the applied EDN3 antibody by use of competitive blocking peptide in immunohistochemistry.
###end p 90
###begin p 91
Click here for file
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
###xml 275 282 <span type="species:ncbi:9606">patient</span>
###xml 428 435 <span type="species:ncbi:9606">patient</span>
###xml 787 792 <span type="species:ncbi:9606">Human</span>
The excellent technical assistance from Sonja von Serenyi, Sevim Alkaya and Inge Losen is greatly appreciated. We thank Dieter Niederacher (Heinrich-Heine University, Dusseldorf, Germany) and Matthias Durst (Friedrich-Schiller University, Jena, Germany) for kindly providing patient samples. We thank Monika Klinkhammer-Schalke and Felicitas Horn (Tumour Registry, Regensburg, Germany) for continuous help in obtaining clinical patient information and follow-up data. Immunohistochemical scoring was kindly performed by Nuran Bektas (Institute of Pathology, University Hospital of the RWTH, Aachen, Germany). HMEC DNA was a generous gift by Bernhard Luscher (Institute of Biochemistry, University Hospital of the RWTH, Aachen, Germany). This work is a research project within the German Human Genome Project and was supported by a grant from the Bundesministerium fur Bildung und Forschung (BMBF) to ED (01KW040-1).
###end p 93
###begin article-title 94
Endothelins and hypoxia-inducible factor in cancer
###end article-title 94
###begin article-title 95
Endothelins
###end article-title 95
###begin article-title 96
The endothelin family: an overview
###end article-title 96
###begin article-title 97
A role for endothelin-2 and its receptors in breast tumor cell invasion
###end article-title 97
###begin article-title 98
The endothelin axis: a novel target for pharmacotherapy of female malignancies
###end article-title 98
###begin article-title 99
Endothelin receptors and calcium signaling
###end article-title 99
###begin article-title 100
Endothelin as autocrine regulators of tumor cell growth
###end article-title 100
###begin article-title 101
Emerging role of the endothelin axis in ovarian tumour progression
###end article-title 101
###begin article-title 102
Involvement of endothelin receptors in normal and pathological development of neural crest cells
###end article-title 102
###begin article-title 103
Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma
###end article-title 103
###begin article-title 104
Endothelins may modulate invasion and proliferation of Ewing's sarcoma and neuroblastoma
###end article-title 104
###begin article-title 105
Endothelins in breast tumour cell invasion
###end article-title 105
###begin article-title 106
Endothelin receptors as novel targets in tumor therapy
###end article-title 106
###begin article-title 107
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells
###end article-title 107
###begin article-title 108
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer
###end article-title 108
###begin article-title 109
Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells
###end article-title 109
###begin article-title 110
###xml 102 106 <span type="species:ncbi:9615">dogs</span>
Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs
###end article-title 110
###begin article-title 111
###xml 84 88 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Pulmonary expression of preproET-1 and preproET-3 mRNAs is altered re ciprocally in rats after inhalation of air pollutants
###end article-title 111
###begin article-title 112
Method for grading breast cancer
###end article-title 112
###begin article-title 113
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies
###end article-title 113
###begin article-title 114
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
###end article-title 114
###begin article-title 115
Real-time quantitative RT-PCR after laser-assisted cell picking
###end article-title 115
###begin article-title 116
Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue
###end article-title 116
###begin article-title 117
MethPrimer: designing primers for methylation PCRs
###end article-title 117
###begin article-title 118
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 118
###begin article-title 119
Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer
###end article-title 119
###begin article-title 120
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer
###end article-title 120
###begin article-title 121
###xml 45 50 <span type="species:ncbi:9606">human</span>
A comparison of X-ray and NMR structures for human endothelin-1
###end article-title 121
###begin article-title 122
Epigenetic gene silencing in cancer: the DNA hypermethylome
###end article-title 122
###begin article-title 123
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
###end article-title 123
###begin article-title 124
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways
###end article-title 124
###begin article-title 125
Endothelin-1 as a target for therapeutic intervention
###end article-title 125
###begin article-title 126
###xml 71 76 <span type="species:ncbi:9606">human</span>
Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up
###end article-title 126
###begin article-title 127
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors
###end article-title 127
###begin article-title 128
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation
###end article-title 128
###begin article-title 129
Aberrant promoter methylation of EDNRB in lung cancer in Taiwan
###end article-title 129
###begin article-title 130
The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells
###end article-title 130
###begin article-title 131
###xml 58 63 <span type="species:ncbi:9606">human</span>
Hypermethylation of CpG islands in primary and metastatic human prostate cancer
###end article-title 131
###begin article-title 132
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients
###end article-title 132
###begin article-title 133
Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor
###end article-title 133
###begin article-title 134
Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan
###end article-title 134
###begin article-title 135
Identification of aberrant promoter methylation of EDNRB gene in esophageal squamous cell carcinoma
###end article-title 135
###begin article-title 136
Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma
###end article-title 136
###begin article-title 137
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan
###end article-title 137
###begin article-title 138
Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells
###end article-title 138
###begin article-title 139
Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis
###end article-title 139
###begin article-title 140
The endothelin axis: emerging role in cancer
###end article-title 140
###begin article-title 141
###xml 142 151 142 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 155 162 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 118 123 <span type="species:ncbi:9606">human</span>
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo
###end article-title 141
###begin article-title 142
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade
###end article-title 142
###begin article-title 143
Endothelin receptor A blockade enhances taxane effects in prostate cancer
###end article-title 143
###begin article-title 144
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
###end article-title 144
###begin article-title 145
Highlights on endothelins: a review
###end article-title 145

